The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The VENTANA HER2 (4B5) test is also now approved to help identify patients with...
Hence then, the article about roche receives ce ivdr approval for her2 4b5 companion diagnostic test to identify her2 ultralow breast cancer and biliary tract cancer patients was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients )
Also on site :
- Юридическая фирма Kasowitz LLP опубликовала актуализированный отчет, посвященный анализу нарушений фундаментальных процессуальных норм как основания для дальнейшего содержания под стражей и судебного преследования мэра Тираны (Албания) Эрио
- Asia rolls out four-day weeks and work-from-home as emergency measures to solve a fuel crisis caused by Iran war
- Massive fires on two oil tankers after attack in Iraqi waters